Delivery Order SPE2DR25D1109-SPE2DR26FFH6F
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,226.80 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens, with an award date of August 25, 2025 and ultimate completion date of August 26, 2025. This non-competitive, firm fixed-price delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $1,048.37 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of August 12, 2025. This is a firm fixed price, non-set-aside contract executed on August 11, 2025, with performance at the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens valued at $1,517.85, with completion expected by September 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a routine pharmaceutical procurement supporting federal medical supply needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $1,403.84 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on August 5, 2025, with completion expected by August 6, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical supply transaction executed without set-aside provisions. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $1,388.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Lantus SoloStar 100 Unit/mL insulin pens (3mL). This is a non-set-aside award with a completion date of November 14, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is one of the nation's largest pharmaceutical distributors and serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a $1,163.64 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens (3mL units) with an ultimate completion date of November 19, 2025. This non-set-aside, firm fixed-price contract represents a competitively awarded delivery order issued under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be performed and delivered from the contractor's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,033.47 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract was competitively awarded without set-aside designation under a firm fixed-price arrangement, with performance scheduled for completion by August 18, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $1,278.50 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of October 30, 2025. The contract was competitively awarded without set-aside designation under a firm fixed price arrangement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement across military and...
- The Defense Logistics Agency awarded a $4,157.91 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ml 3ml insulin pens, with an ultimate completion date of October 29, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $4,253.11 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract was awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, under a firm fixed-price arrangement with no set-aside designation. Performance will be executed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFH6FDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,206.86 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with a completion date of December 9, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive procurement of pharmaceutical supplies for federal medical needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for the Defense Logistics Agency's medical supply chain and holds a substantial Indefinite Delivery Contract (IDC) valued at $999,999,999.00 through December 2026 under the DLA Troop Support Medical contract vehicle (SPE2DX). This delivery order falls under AmerisourceBergen Drug Corp's broader Pharmaceutical Prime Vendor Global Program relationship with the Defense Logistics Agency, which supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's contract portfolio with DLA demonstrates consistent capability in delivering both brand-name and generic medications across multiple therapeutic domains, including diabetes treatments, to serve the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The firm fixed-price structure and competitive award process reflect the company's qualification to meet federal procurement requirements for critical medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 12/7/25 |